Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.57 USD
Change Today +0.01 / 0.12%
Volume 237.5K
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

repros therapeutics inc (RPRX) Snapshot

Open
$8.52
Previous Close
$8.56
Day High
$8.70
Day Low
$8.36
52 Week High
09/2/14 - $22.55
52 Week Low
10/21/14 - $5.92
Market Cap
208.0M
Average Volume 10 Days
362.3K
EPS TTM
$-1.38
Shares Outstanding
24.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REPROS THERAPEUTICS INC (RPRX)

repros therapeutics inc (RPRX) Related Bloomberg News

View More Bloomberg News

repros therapeutics inc (RPRX) Related Businessweek News

No Related Businessweek News Found

repros therapeutics inc (RPRX) Details

Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders in the United States. Its product portfolio includes Androxal, an oral therapy, which is in Phase III clinical trials for the treatment of low testosterone due to secondary hypogonadism; and Proellex that is in Phase II clinical trials for the treatment of symptoms associated with uterine fibroids and endometriosis. The company has a license agreement with the National Institutes of Health to develop and commercialize Proellex. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas.

28 Employees
Last Reported Date: 03/16/15
Founded in 1987

repros therapeutics inc (RPRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $521.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $275.0K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $191.3K
Chief Medical Officer
Total Annual Compensation: $181.1K
Vice President of Research & Development
Total Annual Compensation: $183.3K
Compensation as of Fiscal Year 2013.

repros therapeutics inc (RPRX) Key Developments

Repros Therapeutics Inc. expected to report Fiscal Year 2014 results on March 28, 2015. This event was calculated by Capital IQ (Created on March 22, 2015).

Repros Therapeutics Inc. expected to report Fiscal Year 2014 results on March 28, 2015. This event was calculated by Capital IQ (Created on March 22, 2015).

Repros Therapeutics Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Repros Therapeutics Inc. announced consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenues of $3,000 against $4,000 a year ago. Net loss was $7,446,000 against $7,314,000 a year ago. Basic and diluted net loss per share was $0.31 against $0.32 a year ago. The increase in net loss for the three month period ended December 31, 2014 as compared to the same period in 2013 was primarily due to increased payroll and benefits, partially offset by a decreased clinical development expenses related to Androxal and Proellex. For the year, the company reported total revenues of $9,000 against $9,000 a year ago. Net loss was $32,535,000 against $28,466,000 a year ago. Basic and diluted net loss per share was $1.39 against $1.37 a year ago. The increase in net loss for the twelve month period ended December 31, 2014 as compared to 2013 was primarily due to increased expenses in clinical development related to Androxal®, payroll and benefits, non-cash stock based compensation and professional services costs. Net cash of approximately $29.3 million was used in operating activities during the year ended December 31, 2014 as compared to $25.3 million for the year ended December 31, 2013.

Repros Therapeutics Inc. Submits New Drug Application to FDA for Androxal

Repros Therapeutics Inc. reported that it has electronically submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Androxal, the company's lead product candidate. Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound. The company is developing Androxal for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. Androxal is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism. Secondary hypogonadism due to being overweight or obese is the single great cause of hypogonadism in general.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RPRX:US $8.57 USD +0.01

RPRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RPRX.
View Industry Companies
 

Industry Analysis

RPRX

Industry Average

Valuation RPRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REPROS THERAPEUTICS INC, please visit www.reprosrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.